Having spent nearly a decade at NASH-focused NGM Bio, Aetna Wun Trombley knew it would take some really compelling science to lure her away: “I was at NGM for nine years and I still love that company, ...

Venrock Healthcare Capital Partners led the round, with participation from new investors Janus Henderson Investors, Marshall Wace and Franklin Templeton, and continued support from existing investors ...

Eli Lilly is signing another protein degradation partner, signaling a growing commitment to the space, which seeks to tackle “undruggable” targets. The Big Pharma is handing over $35 million and ...

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the completion of an oversubscribed $70 million ...

The emerging class of therapies that treat disease by using the cellular process of protein degradation focused first on cancer. But this approach also has potential applications in immunology, and ...

SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--Biotechnology company Lycia Therapeutics, Inc. today exited stealth mode with a $50 million commitment from founding investor Versant Ventures. Proceeds are ...

(RTTNews) - Eli Lilly and Company (LLY) has entered into a research collaboration and licensing agreement with Lycia Therapeutics to address key unmet medical needs in Lilly's therapeutic areas of ...

Targeted protein degradation offers the potential to address tough-to-treat diseases, but the first wave of these experimental therapies only addresses disease-causing proteins inside of a cell. Eli ...

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal with Lycia Therapeutics spanning up to five drug targets. The pharma company ...

For over two decades, Arizona's Lycia have been pioneers of “darkwave,” a reverb-drenched, gothic take on dreampop. Quiet Moments, their first release for Handmade Birds, is a somber, but beautiful ...